Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus Doxorubicin in Advanced Soft Tissue Sarcoma
NCT04910126Phase 2Unknown
- Start
- Nov 2020
- Primary completion
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camrelizumab in soft tissue sarcoma (STS) (2 arms). Primary endpoint: Progression-Free Survival at 3 years. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04910126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04910126.